Comparison in a real world setting of the safety and efficacy of two treatment regimens (isatuximab vs elotuzumab) in patients affected by multiple myeloma (MM), adopting a target trial emulation (TTE) approach. Results: Both triplets (IsaPd and EloPd) produce comparable survival outcomes, with distinct toxicity profiles. EloPd potentially offers a lower risk of infections, which may be relevant for patient selection in cases in which infection risk is a major concern. Nevertheless, daratumumab refractoriness remains a dominant predictor of outcomes, representing an unmet clinical needBoth triplets (IsaPd and EloPd) produce comparable survival outcomes, with distinct toxicity profiles. EloPd potentially offers a lower risk of infections, which may be relevant for patient selection in cases in which infection risk is a major concern. Nevertheless, daratumumab refractoriness remains a dominant predictor of outcomes, representing an unmet clinical need
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomide-dexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data
Pitino A.Co-primo
;Tripepi G.;
2025
Abstract
Comparison in a real world setting of the safety and efficacy of two treatment regimens (isatuximab vs elotuzumab) in patients affected by multiple myeloma (MM), adopting a target trial emulation (TTE) approach. Results: Both triplets (IsaPd and EloPd) produce comparable survival outcomes, with distinct toxicity profiles. EloPd potentially offers a lower risk of infections, which may be relevant for patient selection in cases in which infection risk is a major concern. Nevertheless, daratumumab refractoriness remains a dominant predictor of outcomes, representing an unmet clinical needBoth triplets (IsaPd and EloPd) produce comparable survival outcomes, with distinct toxicity profiles. EloPd potentially offers a lower risk of infections, which may be relevant for patient selection in cases in which infection risk is a major concern. Nevertheless, daratumumab refractoriness remains a dominant predictor of outcomes, representing an unmet clinical needI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
